Effectiveness and Safety of Flumazenil Augmentation During Electroconvulsive Therapy.
Journal
The journal of ECT
ISSN: 1533-4112
Titre abrégé: J ECT
Pays: United States
ID NLM: 9808943
Informations de publication
Date de publication:
12 Feb 2024
12 Feb 2024
Historique:
medline:
19
2
2024
pubmed:
19
2
2024
entrez:
19
2
2024
Statut:
aheadofprint
Résumé
Benzodiazepines are considered to negatively affect seizure quality and duration during electroconvulsive therapy (ECT). Several researchers have advocated the use of flumazenil, a competitive benzodiazepine receptor antagonist, for patients treated with benzodiazepines during ECT. However, clinical evidence regarding flumazenil use in ECT remains sparse. The aim of this study is to investigate the effects of flumazenil on seizure duration and adverse effects. All patients with depressive disorders, treated with flumazenil during a course of ECT in 2019 in a tertiary hospital, were identified through a retrospective chart review. Seizure duration was recorded before and after flumazenil administration. Effectiveness of ECT was assessed using the Inventory of Depressive Symptomatology and the Bush-Francis Catatonia Rating Scale. Postictal agitation was ascertained by identifying patients who received additional sedatives immediately after ECT or who needed physical restraint. Twenty-six patients were included, receiving a total of 363 treatments, of which 263 were augmented with flumazenil. Flumazenil administration increased electroencephalogram seizure duration on average with 10.5 seconds comparing ECT with or without flumazenil (P = 0.003). In 21.8% of the cases, no increase in seizure duration was observed. Postictal agitation occurred at least once in 34.6% of the patients receiving flumazenil during their course of ECT. Our results show that flumazenil increases seizure duration, albeit with limited clinical implications. Noteworthy, the prevalence of postictal agitation is high. When confronted with short seizures, clinicians should therefore deploy other available techniques to lower seizure threshold before considering flumazenil.
Identifiants
pubmed: 38373168
doi: 10.1097/YCT.0000000000001003
pii: 00124509-990000000-00145
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest or financial disclosures to report.
Références
Stromgren LS, Dahl J, Fjeldborg N, et al. Factors influencing seizure duration and number of seizures applied in unilateral electroconvulsive therapy. Anaesthetics and benzodiazepines. Acta Psychiatr Scand. 1980;62:158–165.
Boylan LS, Haskett RF, Mulsant BH, et al. Determinants of seizure threshold in ECT: benzodiazepine use, anesthetic dosage, and other factors. J ECT. 2000;16:3–18.
Jha A, Stein G. Decreased efficacy of combined benzodiazepines and unilateral ECT in treatment of depression. Acta Psychiatr Scand. 1996;94:101–104.
Pettinati H. Benzodiazepines and unilateral ECT. Nurs Times. 1990;86:50.
The Royal College of Psychiatrists. The ECT Handbook. 4th ed. Cambridge, United Kingdom: Cambridge University Press; 2019.
Weiss A, Hussain S, Ng B, et al. Royal Australian and New Zealand College of Psychiatrists professional practice guidelines for the administration of electroconvulsive therapy. Aust N Z J Psychiatry. 2019;53:609–623.
Petrides G, Divadeenam KM, Bush G, et al. Synergism of lorazepam and electroconvulsive therapy in the treatment of catatonia. Biol Psychiatry. 1997;42:375–381.
Krystal AD, Watts BV, Weiner RD, et al. The use of flumazenil in the anxious and benzodiazepine-dependent ECT patient. J ECT. 1998;14:5–14.
Unal A, Bulbul F, Alpak G, et al. Effective treatment of catatonia by combination of benzodiazepine and electroconvulsive therapy. J ECT. 2013;29:206–209.
Bailine SH, Safferman A, Vital-Herne J, et al. Flumazenil reversal of benzodiazepine-induced sedation for a patient with severe pre-ECT anxiety. Convuls Ther. 1994;10:65–68.
Yi J, Torres J, Azner Y, et al. Flumazenil pretreatment in benzodiazepine-free patients: a novel method for managing declining ECT seizure quality. J ECT. 2012;28:185–189.
Hunkeler W, Möhler H, Pieri L, et al. Selective antagonists of benzodiazepines. Nature. 1981;290:514–516.
Brogden RN, Goa KL. Flumazenil. A reappraisal of its pharmacological properties and therapeutic efficacy as a benzodiazepine antagonist. Drugs. 1991;42:1061–1089.
Wachtel LE, Reti IM, Ying H. Stability of intraocular pressure after retinal reattachment surgery during electroconvulsive therapy for intractable self-injury in a 12-year-old autistic boy. J ECT. 2014;30:73–76.
Hanania MM. Flumazenil reversal of benzodiazepine sedation before electroconvulsive therapy. Anesthesiology. 1995;82:321.
Suzuki K, Takano T, Fujiyama K, et al. Panic attack associated with flumazenil at electroconvulsive therapy session. J ECT. 2009;25:145.
Kellner CH. Handbook of ECT: A Guide to Electroconvulsive Therapy for Practitioners. Cambridge, United Kingdom: Cambridge University Press; 2019.
Swartz CM. Postictal agitation syndrome or anxiety symptoms. J ECT. 2014;30:e27.
Tzabazis A, Schmitt HJ, Ihmsen H, et al. Postictal agitation after electroconvulsive therapy: incidence, severity, and propofol as a treatment option. J ECT. 2013;29:189–195.
Devanand DP, Briscoe KM, Sackeim HA. Clinical features and predictors of postictal excitement. Convuls Ther. 1989;5:140–146.
Kikuchi A, Yasui-Furukori N, Fujii A, et al. Identification of predictors of post-ictal delirium after electroconvulsive therapy. Psychiatry Clin Neurosci. 2009;63:180–185.
Swartz CM. Electroconvulsive therapy emergence agitation and succinylcholine dose. J Nerv Ment Dis. 1990;178:455–457.
Feenstra TC, Blake Y, Hoogendoorn AW, et al. Pharmacological prevention of postictal agitation after electroconvulsive therapy—a systematic review and meta-analysis. Front Psych. 2023;14:1170931.
Sterina E, Gregory N, Hermida AP. Acute and prophylactic management of postictal agitation in electroconvulsive therapy. J ECT. 2023;39:136–140.
Gomez-Arnau J, de Arriba-Arnau A, Correas-Lauffer J, et al. Hyperventilation and electroconvulsive therapy: a literature review. Gen Hosp Psychiatry. 2018;50:54–62.
Kranaster L, Hoyer C, Mindt S, et al. The novel seizure quality index for the antidepressant outcome prediction in electroconvulsive therapy: association with biomarkers in the cerebrospinal fluid. Eur Arch Psychiatry Clin Neurosci. 2020;270:911–919.
Mayur P. Ictal electroencephalographic characteristics during electroconvulsive therapy: a review of determination and clinical relevance. J ECT. 2006;22:213–217.